R
Robert H. Shoemaker
Researcher at National Institutes of Health
Publications - 216
Citations - 23122
Robert H. Shoemaker is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Cancer & DNA damage. The author has an hindex of 55, co-authored 197 publications receiving 21697 citations. Previous affiliations of Robert H. Shoemaker include University of Bologna & Strong Memorial Hospital.
Papers
More filters
Journal ArticleDOI
Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model.
Johannes Gebert,Johannes Gebert,Ozkan Gelincik,Mine Oezcan-Wahlbrink,Mine Oezcan-Wahlbrink,Jason D. Marshall,Alejandro Hernandez-Sanchez,Alejandro Hernandez-Sanchez,Katharina Urban,Katharina Urban,Mark D. Long,Eduardo Cortes,Elena Tosti,Eva Maria Katzenmaier,Eva Maria Katzenmaier,Yurong Song,Ali Elsaadi,Nan Deng,Eduardo Vilar,Vera Fuchs,Vera Fuchs,Nina Nelius,Nina Nelius,Yan P. Yuan,Aysel Ahadova,Aysel Ahadova,Shizuko Sei,Robert H. Shoemaker,Asad Umar,Lei Wei,Song Liu,Peer Bork,Peer Bork,Winfried Edelmann,Magnus von Knebel Doeberitz,Magnus von Knebel Doeberitz,Steven M. Lipkin,Matthias Kloor,Matthias Kloor +38 more
TL;DR: In this paper, a set of shared immunogenic frameshift peptides (FSPs) were selected based on repeat length, gene expression, and mutation frequency to identify candidates for FSP vaccination.
Journal ArticleDOI
A potential role for imaging technology in anticancer efficacy evaluations.
M. Hollingshead,Carrie Bonomi,Suzanne Borgel,John Carter,Robert H. Shoemaker,Giovanni Melillo,Edward A. Sausville +6 more
TL;DR: Transgenic mice bearing a luciferase reporter mechanism can be used to monitor the tumour microenvironment as well as to signal when transforming events occur, which has the potential to reshape the efficacy evaluations and drug-testing algorithms of the future.
Journal ArticleDOI
Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors.
Lars H. Jensen,Annemette Thougaard,Morten Grauslund,Birgitte Søkilde,Elisabeth V. Carstensen,Henrik Dvinge,Dominic A. Scudiero,Peter Buhl Jensen,Robert H. Shoemaker,Maxwell Sehested +9 more
TL;DR: NSC35866 could antagonize etoposide-induced cytotoxicity and DNA breaks in human and murine cancer cells, confirming that NSC358 66 also functions as a catalytic topoisomerase II inhibitor in cells.
Journal ArticleDOI
Development of recombinant adeno-associated virus vectors carrying small interfering RNA (shHec1)-mediated depletion of kinetochore Hec1 protein in tumor cells.
Lina Li,Linda Yang,Dominic A. Scudiero,Miller Sa,Yu Zx,Stukenberg Pt,Robert H. Shoemaker,Robert M. Kotin +7 more
TL;DR: The experiments with rAAV-shRNA vectors demonstrate the utility of producing vectors in invertebrate cells to obtain sufficient concentrations and quantities for solid tumor therapy, and addresses an important requirement for cancer gene therapy.
Journal ArticleDOI
Structural Characterization of Inhibitor Complexes with Checkpoint Kinase 2 (Chk2), a Drug Target for Cancer Therapy.
George T. Lountos,Andrew G. Jobson,Joseph E. Tropea,Christopher Self,Guangtao Zhang,Yves Pommier,Robert H. Shoemaker,David S. Waugh +7 more
TL;DR: In this article, the catalytic domain structures of Chk2 in complex with a novel series of potent and selective small molecule inhibitors have been reported, which can be exploited for the structure-assisted design of novel chemotherapeutics.